ETFs Exact Sciences Corporation

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-23 pm EDT			5-day change	1st Jan Change
52.54 ^USD	-0.91%		-1.43%	-6.50%

Jun. 04	Exact Sciences Corporation, Q1 2025 Earnings Call, May 01, 2025
Jun. 03	Exact Sciences Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 08:40 AM

ETFs positioned on Exact Sciences Corporation

Name	Weight	AuM	1st Jan change
LEVERAGE SHARES PLC - LS ARK GENOMIC REVOLUTION TRACKER ETP	6.8%	1 M€	-8.38%	-
LEVERAGE SHARES -3X SHORTARKINNOVATION ETP SECURITIES - USD	4.89%	0 M€	0.00%	-
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD	2.49%	1 M€	-.--%	-
HARTFORD LARGE CAP GROWTH ETF - USD	1.11%	126 M€	-0.42%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.34%	21 M€	+1.41%	-
AMUNDI MSCI USA ESG LEADERS SELECT - UCITS ETF DR (C) - USD	0.09%	0 M€	-.--%	-
LYXOR MSCI USA ESG LEADERS EXTRA (DR) UCITS ETF - ACC - USD	0.08%	0 M€	-.--%	-
HSBC MSCI USA UCITS ETF - USD	0.04%	38 M€	-0.54%	-
RAREVIEW SYSTEMATIC EQUITY ETF - USD	0.03%	59 M€	+1.26%	-
VANGUARD US TOTAL MARKET SHARES INDEX ETF	0.03%	293,477 M€	-2.47%	-
AMUNDI INDEX MSCI WORLD - UCITS ETF DR (C) - EUR	0.03%	0 M€	-.--%	-
AMUNDI INDEX MSCI WORLD UCITS ETF DR (D) - EUR	0.03%	0 M€	-.--%	-
LYXOR MSCI WORLD CLIMATE CHANGE (DR) UCITS ETF - ACC - USD	0.03%	0 M€	-.--%	-
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB - UCITS ETF DR (C) - USD	0.02%	0 M€	-.--%	-
AMUNDI MSCI WORLD CLIMATE PARIS ALIGNED PAB UCITS ETF DR (C) - USD	0.02%	0 M€	-.--%	-

1 2

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Companyâs products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Companyâs flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patientâs breast tumor tissue.

Employees

6,950

Sector

Biotechnology & Medical Research

Calendar

Aug. 04 - Q2 2025 Earnings Release (Projected)

More about the company